Cell-Based Assays Market Prospects Reviewed by Visiongain

15 Mar 2012 • by Natalie Aster

Looking ahead to 2022, many commercial opportunities exist for cell-based testing. Greater need for cellular information earlier in pre-clinical product development stimulates demand for the tests. At present, half of all assays used in pharmaceutical development are cell-based. Miniaturisation and automation are important.

This decade, drug screening and toxicity testing will be important applications for cell-based products and services, shows new Visiongain's “Cell-Based Assays: World Market Prospects 2012-2022” study. The report identifies how the use of tests is increasing in drug discovery and development.

The report identifies potential revenues and other trends, with data, forecasts and discussions. It analyses products and services for cell-based testing. It covers activities of product developers and pre-clinical contract research organizations.

Sales predictions to 2022 are provided at world market, main submarket and national levels.

Report Details:

Cell-Based Assays: World Market Prospects 2012-2022
Published: January, 2012
Pages: 124
Price: US$ 2.642,00

Wide scope for developing the systems and applications from 2012 to 2022 seeing many opportunities is identified by the report.

Visiongain's study provides data, analysis and opinion aiming to benefit research, calculations and presentations.

More information can be found in the report “Cell-Based Assays: World Market Prospects 2012-2022” by Visiongain.

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com